Until approximately 2014, the primary cause of tumor defects in the MMR pathway (other than MLH1 promoter hypermethylation or BRAF V600E mutation) was thought to be LS, and patients were often counseled that they likely had LS even in the absence of a germline PV. Here, BRAF is linked to neoplasm.